EGFR and non-small cell lung carcinoma: The results showed that for patients with EGFR-mutated NSCLC that progressed to LM after treatment with third-generation EGFR-TKIs, EGFR C797S was the most frequently detected mutation in CSF and its level decreased with improvements in radiation or neurological function, whereas T790M mutation levels in plasma were significantly elevated before disease progression, suggesting that nanowire technology-based CSF cfDNA genotyping could be feasible and effective for guiding LM therapy in patients with EGFR-mutated NSCLC [102].